A Phase II clinical trial is currently evaluating the anti-tumor effect and immunogenicity of anti-B7H3 (Enoblituzumab) neoadjuvant therapy given to patients prior to radical prostatectomy (NCT02923180). Here, CD276 is linked to neoplasm.